玻璃体内注射血管内皮生长因子抑制剂：实用方法
Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach.
作者信息
Petri Anne-Sofie, Boysen Kirstine, Cehofski Lasse J, van Dijk Elon H C, Dysli Chantal, Fuchs Josefine, Mastropasqua Rodolfo, Subhi Yousif
机构信息
Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark.
Department of Ophthalmology, Odense University Hospital, Odense, Denmark.
出版信息
Ophthalmol Ther. 2020 Mar;9(1):191-203. doi: 10.1007/s40123-020-00230-4. Epub 2020 Feb 7.
Abstract
Intravitreal injections with vascular endothelial growth factor inhibitors constitute the most prevalent ophthalmic procedure in developed countries. Historically, there has been steady growth in the number of treatments performed of this kind, and projection studies estimate further growth in such treatments in the future. We provide a practical approach to intravitreal injections and discuss important aspects relating to the setting, the patient, the procedure, and the information given to the patient.
摘要
玻璃体内注射血管内皮生长因子抑制剂是发达国家最常见的眼科手术。从历史上看，这类治疗的实施数量一直在稳步增长，预测研究估计未来此类治疗还会进一步增加。我们提供了一种玻璃体内注射的实用方法，并讨论了与治疗环境、患者、手术过程以及向患者提供的信息相关的重要方面。
相似文献
1
Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach.玻璃体内注射血管内皮生长因子抑制剂：实用方法
Ophthalmol Ther. 2020 Mar;9(1):191-203. doi: 10.1007/s40123-020-00230-4. Epub 2020 Feb 7.
2
Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease.评估有和无糖尿病肾病的患者长期玻璃体内抗血管内皮生长因子注射对肾功能的影响。
BMC Nephrol. 2019 Dec 26;20(1):478. doi: 10.1186/s12882-019-1650-1.
3
Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.同一天行双侧玻璃体内抗血管内皮生长因子注射：加拿大一大型视网膜中心的经验。
Ophthalmologica. 2019;242(1):1-7. doi: 10.1159/000499115. Epub 2019 Mar 29.
4
High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.美国玻璃体内注射率和医疗保险每注射一次抗血管内皮生长因子支付费用的高度变化。
Ophthalmology. 2016 Jun;123(6):1257-62. doi: 10.1016/j.ophtha.2016.02.015. Epub 2016 Mar 12.
5
Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.双眼同一天接受抗血管内皮生长因子玻璃体内注射后的眼内炎发生率。
Am J Ophthalmol. 2018 Oct;194:1-6. doi: 10.1016/j.ajo.2018.06.022. Epub 2018 Jul 6.
6
Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.一名接受玻璃体内注射阿柏西普治疗双侧糖尿病性黄斑水肿的患者发生高血压性脑出血且血浆血管内皮生长因子水平检测不到：病例报告
J Med Case Rep. 2021 Jul 27;15(1):403. doi: 10.1186/s13256-021-02983-3.
7
Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.抗血管内皮生长因子注射治疗新生血管性年龄相关性黄斑变性后的玻璃体内黄斑界面。
Ophthalmology. 2015 Aug;122(8):1569-72. doi: 10.1016/j.ophtha.2015.04.028. Epub 2015 May 30.
8
Value of Anti-Vascular Endothelial Growth Factor Gene Therapy for Neovascular Age-Related Macular Degeneration.抗血管内皮生长因子基因治疗新生血管性年龄相关性黄斑变性的价值。
Ophthalmol Retina. 2021 Apr;5(4):357-364. doi: 10.1016/j.oret.2020.08.005. Epub 2020 Aug 17.
9
Effect of Alternate Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor and Steroid for Treatment-Naive Diabetic Macular Edema in a Real-Life Setting.在真实环境中，玻璃体内抗血管内皮生长因子和类固醇交替治疗治疗初治糖尿病性黄斑水肿的效果。
J Ocul Pharmacol Ther. 2020 Sep;36(7):555-562. doi: 10.1089/jop.2020.0012. Epub 2020 May 12.
10
Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Clinical Practice of Single Center: Three-Year Outcomes.单中心临床实践中的抗血管内皮生长因子药物玻璃体腔内注射治疗糖尿病黄斑水肿：三年结局。
Ophthalmic Res. 2021;64(3):483-493. doi: 10.1159/000512300. Epub 2020 Oct 14.
引用本文的文献
1
Global Incidence of Central Serous Chorioretinopathy: A Systematic Review, Meta-analysis, and Forecasting Study.中心性浆液性脉络膜视网膜病变的全球发病率：一项系统评价、荟萃分析及预测研究
Ophthalmol Ther. 2025 Aug 9. doi: 10.1007/s40123-025-01220-0.
2
Treatment Interval Progression and Adherence to Observe-and-Plan Regimen for Neovascular Age-Related Macular Degeneration Treated with Aflibercept 2 mg.阿柏西普2毫克治疗新生血管性年龄相关性黄斑变性的治疗间隔进展及对观察与计划方案的依从性
Ophthalmol Ther. 2025 Mar;14(3):585-597. doi: 10.1007/s40123-025-01095-1. Epub 2025 Feb 3.
3
Suprachoroidal Delivery of Viral and Nonviral Vectors for Treatment of Retinal and Choroidal Vascular Diseases.用于治疗视网膜和脉络膜血管疾病的病毒和非病毒载体的脉络膜上腔递送
Am J Ophthalmol. 2024 Dec 21. doi: 10.1016/j.ajo.2024.12.010.
4
Downregulation of rhodopsin is an effective therapeutic strategy in ameliorating peripherin-2-associated inherited retinal disorders.下调视蛋白是改善 peripherin-2 相关遗传性视网膜疾病的有效治疗策略。
Nat Commun. 2024 Jun 4;15(1):4756. doi: 10.1038/s41467-024-48846-5.
5
Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration.阿柏西普耐药的新生血管性年龄相关性黄斑变性患者换用法替卡滨治疗的短期结局。
Graefes Arch Clin Exp Ophthalmol. 2024 Jul;262(7):2153-2162. doi: 10.1007/s00417-024-06421-0. Epub 2024 Feb 28.
6
Effect of Needle Gauge Size on Pain During Intravitreal Anti-VEGF Injection: A Systematic Review and Network Meta-Analysis.针头规格大小对玻璃体内抗血管内皮生长因子注射时疼痛的影响：一项系统评价和网状Meta分析
Ophthalmol Ther. 2024 Mar;13(3):801-817. doi: 10.1007/s40123-023-00879-7. Epub 2024 Jan 24.
7
Therapeutic effects of herbal medicines in different types of retinopathies: A systematic review.草药对不同类型视网膜病变的治疗作用：一项系统评价。
Avicenna J Phytomed. 2023 Mar-Apr;13(2):118-142. doi: 10.22038/AJP.2022.62423.2977.
8
Anti-VEGF Treatment of Diabetic Macular Edema in Denmark: Incidence, Burden of Therapy, and Forecasting Analyses.丹麦糖尿病性黄斑水肿的抗血管内皮生长因子治疗：发病率、治疗负担及预测分析
J Pers Med. 2023 Mar 18;13(3):546. doi: 10.3390/jpm13030546.
9
Macular Edema in Central Retinal Vein Occlusion Correlates With Aqueous Fibrinogen Alpha Chain.中心性视网膜静脉阻塞的黄斑水肿与房水中纤维蛋白原 α 链相关。
Invest Ophthalmol Vis Sci. 2023 Feb 1;64(2):23. doi: 10.1167/iovs.64.2.23.
10
Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion.阿柏西普干预实验性中心性视网膜静脉阻塞的蛋白质组分析。
Molecules. 2022 May 24;27(11):3360. doi: 10.3390/molecules27113360.
本文引用的文献
1
Risk of Death Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-analysis.与玻璃体内抗血管内皮生长因子治疗相关的死亡风险：系统评价和荟萃分析。
JAMA Ophthalmol. 2020 Jan 1;138(1):50-57. doi: 10.1001/jamaophthalmol.2019.4636.
2
Low health literacy levels in patients with chronic retinal disease.慢性视网膜疾病患者的健康素养水平较低。
BMC Ophthalmol. 2019 Aug 8;19(1):174. doi: 10.1186/s12886-019-1191-1.
3
Indoor hospital air and the impact of ventilation on bioaerosols: a systematic review.室内医院空气与通风对生物气溶胶的影响：系统评价。
J Hosp Infect. 2019 Oct;103(2):175-184. doi: 10.1016/j.jhin.2019.06.016. Epub 2019 Jul 4.
4
Task shifting of intraocular injections from physicians to nurses: a randomized single-masked noninferiority study.将眼内注射从医师转移到护士：一项随机单盲非劣效性研究。
Acta Ophthalmol. 2020 Mar;98(2):139-144. doi: 10.1111/aos.14184. Epub 2019 Jul 3.
5
[Patient's Knowledge after Informed Consent for Intravitreal Injections].[玻璃体腔内注射知情同意后的患者认知情况]
Klin Monbl Augenheilkd. 2021 Jun;238(6):721-726. doi: 10.1055/a-0886-6507. Epub 2019 Jun 19.
6
Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis.雷珠单抗治疗新生血管性年龄相关性黄斑变性患者的全身安全性：一项患者水平的汇总分析。
Ophthalmol Retina. 2018 Nov;2(11):1087-1096. doi: 10.1016/j.oret.2018.04.018. Epub 2018 Jun 11.
7
Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.同一天行双侧玻璃体内抗血管内皮生长因子注射：加拿大一大型视网膜中心的经验。
Ophthalmologica. 2019;242(1):1-7. doi: 10.1159/000499115. Epub 2019 Mar 29.
8
Irrigating the eye after intravitreal injection reduces epithelial damage but not patient discomfort.玻璃体内注射后冲洗眼睛可减少上皮损伤，但不能减轻患者的不适。
Acta Ophthalmol. 2019 Jun;97(4):e670-e671. doi: 10.1111/aos.14014. Epub 2019 Jan 8.
9
Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections.抗血管内皮生长因子玻璃体内注射预防眼内炎的当前证据
J Ophthalmol. 2018 Jul 24;2018:8567912. doi: 10.1155/2018/8567912. eCollection 2018.
10
Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use.系统评价和荟萃分析综述：玻璃体腔内抗血管内皮生长因子药物使用与全身不良事件的相关性。
JAMA Ophthalmol. 2018 May 1;136(5):557-566. doi: 10.1001/jamaophthalmol.2018.0002.
Zotero 插件